Lexeo Therapeutics (LXEO) Share-based Compensation (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Share-based Compensation data on file, last reported at $2.8 million in Q1 2026.

• For the quarter ending Q1 2026, Share-based Compensation fell 25.48% year-over-year to $2.8 million; the trailing twelve-month figure through Mar 2026 stood at $11.2 million (down 19.15% YoY), and the FY2025 full-year result was $12.1 million, down 2.74% from the prior year.
• Share-based Compensation rose to $2.8 million in Q1 2026, from $2.7 million in the prior quarter.
• In the past five years, Share-based Compensation ranged from a high of $3.8 million in Q3 2024 to a low of $397000.0 in Q1 2023.
• A 5-year average of $2.1 million and a median of $2.7 million in 2025 frame the typical range for Share-based Compensation.
• Across the five-year window, Share-based Compensation surged 487.15% in 2024 and plunged 30.05% in 2025, its largest moves.
• Tracing LXEO's Share-based Compensation over 5 years: stood at $521000.0 in 2022, then surged by 54.32% to $804000.0 in 2023, then soared by 336.19% to $3.5 million in 2024, then fell by 22.64% to $2.7 million in 2025, then climbed by 1.55% to $2.8 million in 2026.
• Business Quant data shows LXEO's Share-based Compensation at $2.8 million in Q1 2026, $2.7 million in Q4 2025, and $2.7 million in Q3 2025.